Home LiteratureArticle Details

PMID: 3421267 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Pharmacodynamics and tolerance of oral sustained release ritodrine.

American journal of obstetrics and gynecology ·Vol. 159 ·No. 3 ·1988-09-00 ·Pages 690-5

Witter FR, Benedetti TJ, Petty BG, Feldman AM, Traill TA, Anderson J

Abstract

A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.

MeSH Terms

Administration, Oral Adolescent Adult Delayed-Action Preparations Female Heart Rate, Fetal/drug effects Hemodynamics/drug effects Humans Obstetric Labor, Premature/prevention & control Pregnancy Ritodrine/administration & dosage,adverse effects,pharmacokinetics

Chemicals

Delayed-Action Preparations Ritodrine

Authors & Affiliations

6 authors, click to expand affiliations / ORCID

Witter F R

Johns Hopkins University School of Medicine, Department of Gynecology and Obstetrics, Baltimore, MD 21205.

Benedetti T J

Petty B G

Feldman A M

Traill T A

Anderson J

Article Info

Journal

American journal of obstetrics and gynecology

Abbr.

Am J Obstet Gynecol

ISSN

0002-9378

DOI

10.1016/s0002-9378(88)80036-x

Published

1988-09-00

Pages

690-5

Language

English

Region

United States

NLM ID

0370476

Subset

Grants

NCRR NIH HHS · RR0035 · United States

External Links

PubMed source DOI: 10.1016/s0002-9378(88)80036-x View journal details

Analysis Services

Pharmacodynamics and tolerance of oral sustained release ritodrine.

Contact

WeChat Official Account